The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma
Abstract
PURPOSE: To create a comprehensive algorithm that can predict postoperative renal cell carcinoma (RCC) patient outcomes and response to therapy. PATIENTS AND METHODS: A prospective cohort study was performed with outcome assessment on the basis of chart review of 814 patients who underwent nephrectomy between 1989 and 2000. At diagnosis, M1 or N1/N2M0 metastatic disease (M) was present in 346 patients (43%), whereas 468 patients had no metastatic disease (NM) (N0M0). On the basis of UCLA Integrated Staging System category and the presence of metastases, patients were divided into low-risk (LR), intermediate-risk (IR), and high-risk (HR) groups. Decision boxes integrating tumor-node-metastasis staging, tumor grade, and performance status were compiled for determining a patient’s risk group. RESULTS: NM-LR patients had 91% disease-specific survival at 5 years, lower recurrence rate, and better disease-free survival compared with NM-IR and HR patients. Disease progressed in 50% of NM-HR patients. Disease-specific survival of NM-HR patients who received immunotherapy (IMT) for recurrent disease was similar to that of M-LR patients treated with cytoreductive nephrectomy and adjuvant IMT. Time from recurrence to death for NM-HR patients was inferior to that for M-LR patients. After IMT, approximately 25% of M-LR and 12% of M-IR patients had long-term progression-free survival. M-HR patients did poorly despite IMT. CONCLUSION: Stratifying RCC patients into high-, intermediate-, and low-risk subgroups provides a clinically useful system for predicting outcome and provides a unique tool for risk assignment and outcome analysis. Subclassifying RCC into well-defined risk groups should allow better patient counseling and identification of both NM-HR subgroups that need adjuvant treatment and nonresponders who need alternative therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,715
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Self-citationA POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA
KATTAN, M. W., REUTER, V., MOTZER, R. J., KATZ, J., & RUSSO, P. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66077-6 · Cited by 754
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1649 · Cited by 729
Self-citationPrognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.
Elson, P. J., Witte, R. S., & Trump, D. L. (1988) · PubMed · Cited by 340
Litwin, M. S., Fine, J. T., Dorey, F. J., Figlin, R. A., & Belldegrun, A. S. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64807-9 · Cited by 31
Self-citation
Cited by
Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15590-6 · Cited by 434
Patard, J.-J., Kim, H. L., Lam, J. S., Dorey, F. J., Pantuck, A. J., Zisman, A., Ficarra, V., Han, K.-R., Cindolo, L., De La Taille, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.104 · Cited by 423
Self-citationWood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A. I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60697-2 · Cited by 332
Self-citationClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
Brooks, S. A., Brannon, A. R., Parker, J. S., Fisher, J. C., Sen, O., Kattan, M. W., Hakimi, A. A., Hsieh, J. J., Choueiri, T. K., Tamboli, P., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.035 · Cited by 301
Fan, Y., Li, H., Ma, X., Gao, Y., Chen, L., Li, X., Bao, X., Du, Q., Zhang, Y., & Zhang, X. (2015) · Medicine · doi:10.1097/md.0000000000001646 · Cited by 32
Metadata
- Authors
- Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-12-01
- Volume
- 20
- Issue
- 23
- Pages
- 4559-4566
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2083887116
- Cited by
- 675
- References
- 9
- FWCI
- 14.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2002.05.111
- The paper
- Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2002). Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.05.111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
